PATENT CLAIM ANALYSIS

Application Number: 16121198
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["514", "211150"]

Abstract:
Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).

Claim (Index 37):
A method of treating a disease selected from the group consisting of\n chemotherapy-induced cognitive deficits (CICD), chemotherapy-induced cognitive impairment (CICI), chemotherapy-induced peripheral neuropathy (CIPN), diabetic neuropathy, Alzheimer's disease, amyotrophic lateral sclerosis frontotemporal dementia, Huntington's disease, Kennedy's disease Lewy body disease, Parkinson's disease, progressive supranuclear palsy spinocerebellar ataxia, Traumatic brain injury (TBI), traumatic injury to central nervous system or peripheral nervous system neurons, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein:\n X 1  is selected from C and N; \n X 2  is selected from C and N; \n exactly one of X 1  and X 2  is N; \n X 3  is N; \n X 4  and X 5  are C; \n X 1 , X 2 , X 3 , X 4 , and X 5  form a five membered heteroaryl; \n R 1  is selected from alkyl, cycloalkyl, and heterocycloalkyl, any of which is optionally substituted with one to three R 5  groups; \n R 2  is H or is selected from alkyl, amino, aryl, cycloalkyl, haloalkyl, heteroalkyl, heteroaryl, heterocycloalkyl, and sulfonylalkyl, any of which is optionally substituted with one to three R 6  groups; \n R 3  is selected from H, alkyl, (alkoxy)alkyl, (arylalkoxy)alkyl, (heteroarylalkoxy)alkyl, cyano, cycloalkyl, halo, haloalkoxy, and haloalkyl; \n R 4  is N(R 4a ) 2 , wherein each R 4a  is independently selected from hydrogen, C 1-4 alkyl, and C 1-4 haloalkyl; \n or R 3  and R 4  together with the atoms to which they are attached form a 5- or 6-membered heteroaryl or heteroalkyl ring, optionally substituted with one to three R 7  groups; \n each R 5  and R 6  is independently selected from C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, C 1-4 alkylthio, C 1-4 haloalkylthio, aryl, heteroaryl, C 3-7 cycloalkyl, C 3-7 heterocycloalkyl, (aryl)C 1-4 alkyl, (heteroaryl)C 1-4 alkyl, (C 3-7 cycloalkyl)C 1-4 alkyl, (C 3-7 heterocycloalkyl)C 1-4 alkyl, (ethenyl)C 1-4 alkyl, (ethynyl)C 1-4 alkyl, (aryl)C 1-4 alkoxy, (heteroaryl)C 1-4 alkoxy, (C 3-7 cycloalkyl)C 1-4 alkoxy, (C 3-7 heterocycloalkyl)C 1-4 alkoxy, (aryl)C 1-4 alkylthio, (heteroaryl)C 1-4 alkylthio, (C 3-7 cycloalkyl)C 1-4 alkylthio, (C 3-7 heterocycloalkyl)C 1-4 alkylthio, amino, halo, hydroxy, cyano, and oxo; and \n each R 7  is independently selected from C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, aryl, heteroaryl, C 3-7 cycloalkyl, C 3-7 heterocycloalkyl, (aryl)C 1-4 alkyl, (heteroaryl)C 1-4 alkyl, (C 3-7 cycloalkyl)C 1-4 alkyl, (C 3-7 heterocycloalkyl)C 1-4 alkyl, halo, hydroxy, cyano, and oxo; \n each R 7  is independently selected from C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, aryl, heteroaryl, C 3-7 cycloalkyl, C 3-7 heterocycloalkyl, (aryl)C 1-4 alkyl, (heteroaryl)C 1-4 alkyl, (C 3-7 cycloalkyl)C 1-4 alkyl, (C 3-7 heterocycloalkyl)C 1-4 alkyl, halo, hydroxy, cyano, and oxo.

Metadata:
- Claim Count in Document: 137.0
- Percentile: 97.0
- Lexical Diversity: 1.74157
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15836442', '15199100', '15631417', '11942480', '16035310']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7544624162923214
- 35 USC 102 Novelty (BERT): 0.5236523665118149
- Combined Prediction Score: 0.7313814113142708
- Mean Citation Score: 246.423266
- Max Citation Score: 310.2461
- Similarity Product: 179.8816533875585

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test